Yuhei YAMAGUCHI· @yymgcmd · X·· 1 天前评分45
正文 · 原文
CDK4 inhibitors will likely enter routine breast cancer care.
🧐For 2nd-line endocrine therapy, biomarker-guided treatment based on ESR1, PIK3CA/AKT1/PTEN alterations or CDK4 inhibition?
💡One advantage of CDK4 inhibitors: no CDx required.
#ESMO26
36 浏览 · 3 赞 · 0 转发 · 0 回复
Very promising randomized results with the CDK4 selective inhibitor atirmociclib presented by @antgiorda. Next gen CDKs are here! #ESMO26 #ESMOAmbassadors在 X 查看被引用的帖子
来源：Yuhei YAMAGUCHI · x.com